Interferon-β but not Glatiramer acetate stimulates CXCL10 secretion in primary cultures of thyrocytes: A clue for understanding the different risks of thyroid dysfunctions in patients with multiple sclerosis treated with either of the two drugs

Journal of Neuroimmunology

Volumn 234, Issue 1-2, 2011, Pages 161-164

  Rotondi, Mario ^a   Stufano, Francesca ^a   Lagonigro, Maria Stefania ^a   La Manna, Luigi ^b   Zerbini, Francesca ^a   Ghilotti, Stefania ^a   Pagliari, Maria Teresa ^a   Coperchini, Francesca ^a   Magri, Flavia ^a   Bergamaschi, Roberto ^c   Oliviero, Antonio ^d   Chiovato, Luca ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b IRCCS   (Italy)

^c C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^d HOSPITAL NACIONAL DE PARAPLÉJICOS   (Spain)

Author keywords

Autoimmunity; Chemokines; CXCL10; Glatiramer acetate; Interferons; Thyrocytes

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLATIRAMER; INTERFERON BETA SERINE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL CULTURE; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MONOTHERAPY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; THYROID CELL; THYROID DISEASE; THYROIDECTOMY;

ANALYSIS OF VARIANCE; CELLS, CULTURED; CHEMOKINE CXCL10; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; PEPTIDES; THYROID GLAND;

EID: 79955658313     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2011.01.013     Document Type: Article

References (27)

1. Aharoni R., Teitelbaum D., Sela M., Arnon R. Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc. Natl Acad. Sci. USA 1997, 94:10821-10826.
2. Antonelli A., Rotondi M., Fallahi P., Romagnani P., Ferrari S.M., Paolicchi A., Ferrannini E., Serio M. Increase of interferon-gamma inducible alpha chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis. Eur. J. Endocrinol. 2005, 152:171-177.
3. Antonelli A., Rotondi M., Fallahi P., Romagnani P., Ferrari S.M., Barani L., Ferrannini E., Serio M. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy. Clin. Endocrinol. 2006, 2:189-195.
4. Antonelli A., Rotondi M., Ferrari S.M., Fallahi P., Romagnani P., Franceschini S.S., Serio M., Ferrannini E. Interferon-{gamma}-inducible alpha}-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-{gamma agonists. J. Clin. Endocrinol. Metab. 2006, 91:614-620.
5. Antonelli A., Ferrari S.M., Fallahi P., Ghiri E., Crescioli C., Romagnani P., Vitti P., Serio M., Ferrarini E. Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: modulation by peroxisome proliferator-activated receptor-gamma agonists. Cytokine 2010, 3:260-267.
6. Arnon R. The development of Cop 1 (Copaxone), an innovative drug for the treatment of multiple sclerosis: personal reflections. Immunol. Lett. 1996, 50:1-15.
7. Caraccio N., Dardano A., Manfredonia F., Manca L., Pasquali L., Iudice A., Murri L., Ferrannini E., Monzani F. Long-term follow-up of 106 multiple sclerosis patients undergoing interferon-beta 1a or 1b therapy: predictive factors of thyroid disease development and duration. J. Clin. Endocrinol. Metab. 2005, 90:4133-4137.
8. Charo I.F., Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 2006, 354(6):610-621.
9. Chen M., Gran B., Costello K., Johnson K., Martin R., Dhib-Jalbut S. Glatiramer acetate induces a Th2- biased response and crossreactivity with myeilin basic protein in patients with MS. Mult. Scler. 2001, 7:209-219.
10. Franciotta D., Martino G., Cardini E., Furlan R., Bergamaschi R., Andreoni L., Cosi V. Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J. Neuroimmunol. 2001, 115:192-198.
11. Johnson K.P., Knobler R.L., Greenstein J.L. Recombinant beta interferon treatment of relapsing-remitting multiple sclerosis pilot study results. Neurol 1990, 40:261.
12. Li Q., Milo R., Panitch H., Swoveland P., Bever C.T. Glatiramer acetate blocks the activation of THP-1 cells by interferon-gamma. Eur. J. Pharmacol. 1998, 342:303-310.
13. Mikol D.D., Barkhof F., Chang P., Coyle P.K., Jeffery D.R., Schwid S.R., Stubinski B., Uitdehaag B.M. REGARD study group. Lancet Neurol. 2008, 7:903-914.
14. Milo R., Panitch H. Additive effects of copolymer-1 and interferon beta-1b on the immune response to myelin basic protein. J. Neuroimmunol. 1995, 61:185-193.
15. Monzani F., Caraccio N., Meucci G., Lombardo F., Moscato G., Casolaro A., Ferdeghini M., Murri L., Ferrannini E. Effect of 1-year treatment with interferon-beta1b on thyroid function and autoimmunity in patients with multiple sclerosis. Eur. J. Endocrinol. 1999, 141:325-331.
16. Monzani F., Caraccio N., Dardano A., Ferrannini E. Thyroid autoimmunity and dysfunction associated with type I interferon therapy. Clin. Exp. Med. 2004, 3:199-210.
17. Neuhaus O., Farina C., Yassouriclis A., Wiendl H., Dose T., Wekerle H. Multiple sclerosis comparison of copolymer-1 reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper T helper 2 cells. Proc. Natl Acad. Sci. USA 2000, 97:7452-7457.
18. O'Connor P., Filippi M., Arnason B., Comi G., Cook S., Goodin D., Hartung H.P., Jeffery D., Kappos L., Boateng F., Filippov V., Groth M., Knappertz V., Kraus C., Sandbrink R., Pohl C., Bogumil T., B.E.Y.O.N.D.Study Group 250 microg or 500 microg interferon beta-1b versus 20mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009, 8:889-897.
19. Ohmori Y., Schreiber R.D., Hamilton T.A. Synergy between interferon-γ and tumor necrosis factor-α in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor kB. J. Biol. Chem. 1997, 272:14899-14907.
20. PRISMS (prevention of relapses, disability by Interferon beta-1a subsequently in multiple sclerosis) study group Randomized, double blind, placebo controlled study of interferon beta 1-a in relapsing-remitting multiple sclerosis: clinical results. Lancet 1998, 352:1498-1504.
21. Qin Y., Zhang D.Q., Prat A., Pouly S., Antel J. Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients. J. Neuroimmunol. 2000, 108:201-206.
22. Racke M.K., Lovett-Racke A.E., Karandikar N.J. The mechanism of action of glatiramer acetate treatment in multiple sclerosis. Neurol 2010, 74:25-30.
23. Romagnani P., Rotondi M., Lazzeri E., Lasagni L., Francalanci M., Buonamano A., Milani S., Vitti P., Chiovato L., Tonacchera M., Bellastella A., Serio M. Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' disease. Am. J. Pathol. 2002, 161:195-206.
24. Rotondi M., Oliviero A., Profice P., Mone C.M., Biondi B., Del Buono A., Mazziotti G., Sinisi A.M., Bellastella A., Carella C. Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon-beta therapy for multiple sclerosis. J. Endocrinol. Invest. 1998, 21:748-752.
25. Rotondi M., Mazziotti G., Biondi B., Manganella G., Del Buono A.D., Montella P., Di Cristofaro M., Di Iorio G., Amato G., Carella C. Long-term treatment with interferon-beta therapy for multiple sclerosis and occurrence of Graves' disease. J. Endocrinol. Invest. 2000, 23:321-324.
26. Rotondi M., Chiovato L., Romagnani S., Serio M., Romagnani P. Role of Chemokines in Endocrine Autoimmune Diseases. Endocr. Rev. 2007, 28:492-520.
27. Storch M., Lassmann H. Pathology and pathogenesis of demyelinating diseases. Curr. Opin. Neurol. 1997, 10:186-192.